Aripiprazole and Colorectal Cancer
Author Information
Author(s): Hu Hui‐Fang, Fu Jia‐Ying, Han Lei, Gao Gui‐Bin, Zhang Wei‐Xia, Yu Si‐Ming, Li Nan, Li Yang‐Jia, Lu Yi‐Fan, Ding Xiao‐Feng, Pan Yun‐Long, Wang Yang, He Qing‐Yu
Primary Institution: Jinan University
Hypothesis
Can the antipsychotic drug aripiprazole be repurposed to suppress colorectal cancer through targeting LAMP2a?
Conclusion
Aripiprazole can be repurposed as an effective anticancer drug for colorectal cancer treatment by inducing autophagy and apoptosis.
Supporting Evidence
- Aripiprazole significantly inhibited the growth of colorectal cancer cells with high mTOR expression.
- High LAMP2a expression is associated with poor survival in colorectal cancer patients.
- Aripiprazole induced autophagic apoptosis in colorectal cancer cells.
- LAMP2a is essential for the anticancer effects of aripiprazole.
- Combination treatment of aripiprazole and fluorouracil showed superior therapeutic benefits.
Takeaway
Aripiprazole, a drug usually for mental health, can help fight colon cancer by making cancer cells die and helping the body clean up bad cells.
Methodology
The study used in vitro and in vivo experiments to assess the effects of aripiprazole on colorectal cancer cells and identified LAMP2a as a target through drug affinity response target stability.
Potential Biases
Potential bias in selecting specific cell lines and the interpretation of results may exist.
Limitations
The study primarily focused on specific cancer cell lines and may not fully represent all colorectal cancer types.
Participant Demographics
The study involved human colorectal cancer tissues and cell lines.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website